Kiora Pharmaceuticals
KPRX
15 hedge funds and large institutions have $517K invested in Kiora Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
36% more funds holding
Funds holding: 11 → 15 (+4)
0% more ownership
Funds ownership: 0.02% → 0.02% (+0%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
57% less capital invested
Capital invested by funds: $1.22M → $517K (-$699K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$68K |
| 2 |
E
Ergoteles
New York
|
+$12.8K |
| 3 |
Goldman Sachs
New York
|
+$9.67K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$8.11K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.58K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$54.1K |
| 2 |
Jane Street
New York
|
-$47K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$14.6K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$261 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Geode Capital Management
Boston,
Massachusetts
| $329K | +$4.45K | +17 | +1% |
|
|
2
Renaissance Technologies
New York
| $58K | +$68K | +260 | New |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $48K | -$54.1K | -207 | -49% |
|
4
T. Rowe Price Associates
Baltimore,
Maryland
| $32K | – | – | – |
|
5
BlackRock
New York
| $13K | – | – | – |
|
|
E
6
Ergoteles
New York
| $11K | +$12.8K | +49 | New |
|
|
7
Goldman Sachs
New York
| $8K | +$9.67K | +37 | New |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $7K | +$7.58K | +29 | +2,900% |
|
|
9
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $7K | +$8.11K | +31 | New |
|
10
US Bancorp
Minneapolis,
Minnesota
| $2K | – | – | – |
|
|
11
Osaic Holdings
Scottsdale,
Arizona
| $1K | -$261 | -1 | -25% |
|
12
Citigroup
New York
| $1K | +$784 | +3 | New |
|
|
13
Jane Street
New York
| – | -$47K | -87 | Closed |
|
|
14
UBS Group
Zurich,
Switzerland
| – | -$14.6K | -56 | -98% |
|
KPRX Hedge Fund Activity: Q1 2022 in Review
15 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q1 2022, worth a combined $517K — down 57% from $1.22M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new KPRX positions and 1 closed out — a net gain of 4 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $68K. The largest seller was Vanguard Group, cutting an estimated $54.1K.
- 15 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q1 2022, up from 11 in Q4 2021.
- Funds reported $517K of Kiora Pharmaceuticals stock for Q1 2022, down 57% quarter-over-quarter.
- 5 funds opened new Kiora Pharmaceuticals positions in Q1 2022 and 1 closed out, a net change of +4 holders.
- The largest Kiora Pharmaceuticals buyer in Q1 2022 was Renaissance Technologies, an estimated $68K added.
- The largest Kiora Pharmaceuticals seller in Q1 2022 was Vanguard Group, an estimated $54.1K sold.
Based on aggregated 13F filings for Q1 2022.